Toward Organometallic Antischistosomal Drug Candidates

References

• Hotez PJ , BrindleyPJ, BethonyJM, KingCH, PearceEJ, JacobsonJ. Helminth infections: The great neglected tropical diseases.. J. Clin. Invest.118 (4), 1311–1321 (2008).
   PubMed Web of Science ®Google Scholar
• Colley DG , BustinduyAL, SecorWE, KingCH. Human schistosomiasis. Lancet383 (9936), 2253–2264 (2014).
   PubMed Web of Science ®Google Scholar
• Keiser J , UtzingerJ. The drugs we have and the drugs we need against major helminth infections. Adv. Parasitol.73197–230 (2010).
   PubMed Web of Science ®Google Scholar
• Liu R , DongH-F, GuoY, ZhaoQ-P, JiangM-S. Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and meta-analysis. Parasit. Vectors4 (1), 201 (2011).
   PubMedGoogle Scholar
• Hotez PJ , AlvaradoM, BasanezMGet al. The global burden of disease study 2010: interpretation and implications for the neglected tropical diseases.. PLoS Negl. Trop. Dis.8 (7), e2865 (2014).
   PubMed Web of Science ®Google Scholar
• King CH , Dangerfield-ChaM. The unacknowledged impact of chronic schistosomiasis. Chronic Illn.4 (1), 65–79 (2008).
   PubMedGoogle Scholar
• Trouiller P , OlliaroP, TorreeleE, OrbinskiJ, LaingR, FordN. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet359 (9324), 2188–2194 (2002).
   PubMed Web of Science ®Google Scholar
• Pedrique B , Strub-WourgaftN, SomeCet al. The drug and vaccine landscape for neglected diseases (2000–11): a systematic assessment. Lancet Global Health1 (6), e371–e379 (2013).
   PubMed Web of Science ®Google Scholar
• Njoroge M , NjugunaNM, MutaiP, OngaroraDSB, SmithPW, ChibaleK. Recent approaches to chemical discovery and development against malaria and the neglected tropical diseases human African trypanosomiasis and schistosomiasis. Chem. Rev.114 (22), 11138–11163 (2014).
   PubMed Web of Science ®Google Scholar
• Thétiot-Laurent SaL , BoissierJ, RobertA, MeunierB. Schistosomiasis chemotherapy. Angew. Chem. Int. Ed. Engl.52 (31), 7936–7956 (2013).
   PubMed Web of Science ®Google Scholar
• WHO Fact Sheet No. 115 Schistosomiasis. World Health Organisation, Geneva. www.who.int/mediacentre
   Google Scholar
• Rollinson D , KnoppS, LevitzSet al. Time to set the agenda for schistosomiasis elimination. Acta Trop.128 (2), 423–440 (2013).
   PubMed Web of Science ®Google Scholar
• Hartinger CG , Metzler-NolteN, DysonPJ. Challenges and opportunities in the development of organometallic anticancer drugs. Organometallics31, 5677–5685 (2012).
   Web of Science ®Google Scholar
• Gasser G , Metzler-NolteN. The potential of organometallic complexes in medicinal chemistry. Curr. Opin. Chem. Biol.16, 84–91 (2012).
   PubMed Web of Science ®Google Scholar
• Bruijnincx PC , SadlerPJ. New trends for metal complexes with anticancer activity. Curr. Opin. Chem. Biol.12 (2), 197–206 (2008).
   PubMed Web of Science ®Google Scholar
• Hartinger C , DysonPJ. Bioorganometallic chemistry - from teaching paradigms to medicinal applications. Chem. Soc. Rev.38, 391–401 (2009).
   PubMed Web of Science ®Google Scholar
• Jaouen G , Metzler-NolteN. Medicinal organometallic chemistry. In:Topics in Organometallic Chemistry, Springer, Heidelberg, Germany (2010).
   Google Scholar
• Peacock AFA , SadlerPJ. Medicinal organometallic chemistry: designing metal arene complexes as anticancer agents. Chem. Asian J.3 (11), 1890–1899 (2008).
   PubMed Web of Science ®Google Scholar
• Patra M , GasserG. Organometallic compounds, an opportunity for chemical biology. ChemBioChem13, 1232–1252 (2012).
   PubMed Web of Science ®Google Scholar
• Gasser G . Inorganic chemical biology: principles, techniques and applications. John Wiley & Sons, Ltd, UK (2014).
   Google Scholar
• Salmain M , Metzler-NolteN. Bioorganometallic chemistry of ferrocene. In:Ferrocenes: Ligands, Materials and Biomolecules, StepnickaP ( Ed). Wiley-VCH, Chichester, UK499–639 (2008).
   Google Scholar
• Van Staveren DR , Metzler-NolteN. The bioorganometallic chemistry of ferrocene. Chem. Rev.104, 5931–5985 (2004).
   PubMed Web of Science ®Google Scholar
• Gasser G , OttI, Metzler-NolteN. Organometallic anticancer compounds. J. Med. Chem.54, 3–25 (2011).
   PubMed Web of Science ®Google Scholar
• Patra M , GasserG, Metzler-NolteN. Small organometallic compounds as antibacterial agents. Dalton Trans.41, 6350–6358 (2012).
   PubMed Web of Science ®Google Scholar
• Dive D , BiotC. Ferrocene conjugates of chloroquine and other antimalarials: the development of ferroquine, a new antimalarial. ChemMedChem3 (3), 383–391 (2008).
   PubMed Web of Science ®Google Scholar
• Hillard EA , VessieresA, JaouenG. Ferrocene functionalized endocrine modulators as anticancer agents. In:Medicinal Organometallic Chemistry (Topics in Organometallic Chemistry), JaouenG, Metzler-NolteN ( Eds). Springer, Heidelberg, Germany81–117 (2010).
   Google Scholar
• Martinez A , CarreonT, IniguezEet al. Searching for new chemotherapies for tropical diseases. Ruthenium - clotrimazole complexes display High in vitro activity against Leishmania major and Trypanosoma cruzi and low toxicity toward normal mammalian cells. J. Med. Chem.55 (8), 3867–3877 (2012).
   PubMed Web of Science ®Google Scholar
• Sanchez-Delgado RA , AnzellottiA. Metal complexes as chemotherapeutic agents against tropical diseases: trypanosomiasis, malaria and leishmaniasis. Mini Rev. Med. Chem.4 (1), 23–30 (2004).
   PubMed Web of Science ®Google Scholar
• Iniguez E , SanchezA, VasquezMet al. Metal-drug synergy: new ruthenium(II) complexes of ketoconazole are highly active against Leishmania major and Trypanosoma cruzi and nontoxic to human or murine normal cells. J. Biol. Inorg. Chem.18 (7), 779–790 (2013).
   PubMed Web of Science ®Google Scholar
• Kljun J , ScottAJ, Lanisnik RiznerT, KeiserJ, TurelI. Synthesis and biological evaluation of organoruthenium complexes with azole antifungal agents. First crystal structure of a Tioconazole metal complex. Organometallics33 (7), 1594–1601 (2014).
   Web of Science ®Google Scholar
• Patra M , JoshiT, PierrozVet al. DMSO-mediated ligand dissociation: renaissance for biological activity of N-heterocyclic-[Ru(η6-arene)Cl2] drug candidates. Chem. Eur. J.19 (44), 14768–14772 (2013).
   PubMed Web of Science ®Google Scholar
• Abdulla M-H , RuelasDS, WolffBet al. Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening. PLoS Negl. Trop. Dis.3 (7), e478 (2009).
   PubMed Web of Science ®Google Scholar
• Panic G , DuthalerU, SpeichB, KeiserJ. Repurposing drugs for the treatment and control of helminth infections. Int. J. Parasitol.4 (3), 185–200 (2014).
   Web of Science ®Google Scholar
• Keiser J , UtzingerJ. Antimalarials in the treatment of schistosomiasis. Curr. Pharm. Des.18 (24), 3531–3538 (2012).
   PubMed Web of Science ®Google Scholar
• Keiser J , VargasM, RubbianiR, GasserG, BiotC. In vitro and in vivo antischistosomal activity of ferroquine derivatives. Parasit. Vectors7 (1), 424 (2014).
   PubMedGoogle Scholar
• Navarro M , CastroW, BiotC. Bioorganometallic compounds with antimalarial targets: inhibiting hemozoin formation. Organometallics31 (16), 5715–5727 (2012).
   Web of Science ®Google Scholar
• Salas PF , HerrmannC, OrvigC. Metalloantimalarials. Chem. Rev.113 (5), 3450–3492 (2013).
   PubMed Web of Science ®Google Scholar
• Keiser J , CholletJ, XiaoS-Het al. Mefloquine - An aminoalcohol with promising antischistosomal properties in mice. PLoS Negl. Trop. Dis.3 (1), e350 (2009).
   PubMed Web of Science ®Google Scholar
• Biot C , DaherW, ChavainNet al. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J. Med. Chem.49 (9), 2845–2849 (2006).
   PubMed Web of Science ®Google Scholar
• Jaouen G , Metzler-NolteN. Topics in organometallic chemistry. Springer, Heidelberg, Germany, 1 (2010).
   Google Scholar
• Gryseels B . Schistosomiasis. Infect. Dis. Clin. North Am.26 (2), 383–397 (2012).
   PubMed Web of Science ®Google Scholar
• Cioli D , Pica-MattocciaL, ArcherS. Antischistosomal drugs: past, present… and future?Pharmacol. Ther.68 (1), 35–85 (1995).
   PubMed Web of Science ®Google Scholar
• Huang J , BathenaSPR, AlnoutiY. Metabolite profiling of praziquantel and its analogs during the analysis of in vitro metabolic stability using information-dependent acquisition on a hybrid triple quadrupole linear ion trap mass spectrometer. Drug Metab. Pharmacokinet.25 (5), 487–499 (2010).
   PubMed Web of Science ®Google Scholar
• Doenhoff MJ , CioliD, UtzingerJ. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr. Opin. Infect. Dis.21, 659–667 (2008).
   PubMed Web of Science ®Google Scholar
• Patra M , IngramK, PierrozVet al. [(η6-Praziquantel)Cr(CO)3] Derivatives with remarkable In vitro anti-schistosomal activity. Chem. Eur. J.19 (7), 2232–2235 (2013).
   PubMed Web of Science ®Google Scholar
• Ismail M , BotrosS, MetwallyAet al. Resistance to praziquantel: direct evidance from Schistosoma mansoni isolated from Egyptian villegers. Am. J. Trop. Med. Hyg.60, 932–935 (1999).
   PubMed Web of Science ®Google Scholar
• Melman SD , SteinauerML, CunninghamCet al. Reduced susceptibility to praziquantel among naturally occurring kenyan isolates of schistosoma mansoni. PLoS Negl. Trop. Dis.3 (8), e504 (2009).
   PubMed Web of Science ®Google Scholar
• Greenberg RM . New approaches for understanding mechanisms of drug resistance in schistosomes. Parasitology140, 1534–1546 (2013).
   PubMed Web of Science ®Google Scholar
• Patra M , IngramK, PierrozVet al. Ferrocenyl derivatives of the anthelmintic praziquantel: design, synthesis, and biological evaluation. J. Med. Chem.55 (20), 8790–8798 (2012).
   PubMed Web of Science ®Google Scholar
• Ronketti F , RamanaAV, Chao-MingX, Pica-MattocciaL, CioliD, ToddMH. Praziquantel derivatives I. Modification of the aromatic ring. Bioorg. Med. Chem. Lett.17 (15), 4154–4157 (2007).
   PubMed Web of Science ®Google Scholar
• Laurent SaL , BoissierJ, CoslédanF, GornitzkaH, RobertA, MeunierB. Synthesis of “trioxaquantel” derivatives as potential new antischistosomal drugs. Eur. J. Inorg. Chem. 2008 (5), 895–913 (2008).
   Google Scholar
• Lima RM , FerreiraMaD, PonteTMDJet al. Enantioselective analysis of praziquantel and trans-4-hydroxypraziquantel in human plasma by chiral LC–MS/MS: Application to pharmacokinetics. J. Chromatogr. B877, 3083–3088 (2009).
   PubMed Web of Science ®Google Scholar
• Patra M , IngramK, LeonidovaAet al. In vitro metabolic profile and in vivo antischistosomal activity studies of (n6-Praziquantel)Cr(CO)3 derivatives. J. Med. Chem.56 (22), 9192–9198 (2013).
   PubMed Web of Science ®Google Scholar
• Woelfle M , SeerdenJ-P, De GooijerJ, PouwerK, OlliaroP, ToddMH. Resolution of praziquantel. PLoS Negl. Trop. Dis.5 (9), e1260 (2011).
   PubMed Web of Science ®Google Scholar
• Dong Y , CholletJ, VargasMet al. Praziquantel analogs with activity against juvenile Schistosoma mansoni. Bioorg. Med. Chem. Lett.20, 2481–2484 (2010).
   PubMed Web of Science ®Google Scholar
• Levina A , LayPA. Metal-based anti-diabetic drugs: advances and challenges. Dalton Trans.40 (44), 11675–11686 (2011).
   PubMed Web of Science ®Google Scholar